Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy., PMID:40472844
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy., PMID:40472844
Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624
Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV., PMID:40411624
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial., PMID:40186077
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial., PMID:40186077
Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant., PMID:40009690
Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant., PMID:40009690
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264
Natural killer cell engagers for cancer immunotherapy., PMID:39911822
Natural killer cell engagers for cancer immunotherapy., PMID:39911822
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma., PMID:39904787
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma., PMID:39904787
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors., PMID:39846810
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors., PMID:39846810
Construction and characterization of chimeric FcγR T cells for universal T cell therapy., PMID:39810257
Construction and characterization of chimeric FcγR T cells for universal T cell therapy., PMID:39810257
Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy., PMID:39804516
Impact of Fc-gamma receptor IIIA polymorphism on late-onset neutropenia and clinical outcomes in kidney transplant recipients following rituximab induction therapy., PMID:39804516
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients., PMID:39791733
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients., PMID:39791733
The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells., PMID:39763374
The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells., PMID:39763374
The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing., PMID:39666369
The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing., PMID:39666369
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in Escherichia coli., PMID:39574765
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in Escherichia coli., PMID:39574765
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas., PMID:39531538
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas., PMID:39531538
In utero human cytomegalovirus infection expands NK-like FcγRIII+CD8+ T cells that mediate Fc antibody functions., PMID:39531313
In utero human cytomegalovirus infection expands NK-like FcγRIII+CD8+ T cells that mediate Fc antibody functions., PMID:39531313
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46., PMID:39513028
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46., PMID:39513028
FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients., PMID:39472454
FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients., PMID:39472454
One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa/CD16a structure., PMID:39453384
One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa/CD16a structure., PMID:39453384
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study., PMID:39402708
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia., PMID:39370035
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia., PMID:39370035
FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms., PMID:39359734
FCGR2C Q13 and FCGR3A V176 alleles jointly associate with worse natural killer cell-mediated antibody-dependent cellular cytotoxicity and microvascular inflammation in kidney allograft antibody-mediated rejection., PMID:39332679
FCGR2C Q13 and FCGR3A V176 alleles jointly associate with worse natural killer cell-mediated antibody-dependent cellular cytotoxicity and microvascular inflammation in kidney allograft antibody-mediated rejection., PMID:39332679
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer., PMID:39314954
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer., PMID:39314954
A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide., PMID:39311380
A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide., PMID:39311380
Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis., PMID:39209371
Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis., PMID:39209371
FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population., PMID:39175948
FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population., PMID:39175948
Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity., PMID:39162435
Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity., PMID:39162435
Spatial localization of CD16a at the human NK cell ADCC lytic synapse., PMID:39149244
Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: Nicotiana benthamiana & tobacco BY-2 cell suspension., PMID:39142626
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma., PMID:39100677
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma., PMID:39100677
Selective Recruitment of Antibodies to Cancer Cells and Immune Cell-mediated Killing via In Situ Click Chemistry., PMID:39087480
Selective Recruitment of Antibodies to Cancer Cells and Immune Cell-mediated Killing via In Situ Click Chemistry., PMID:39087480
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:39053944
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:39053944
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers., PMID:39048914
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers., PMID:39048914
Generation of non-genetically modified, CAR-like, NK cells., PMID:39029925
Generation of non-genetically modified, CAR-like, NK cells., PMID:39029925
Affinity-Resolved Size Exclusion Chromatography Coupled to Mass Spectrometry: A Novel Tool to Study the Attribute-and-Function Relationship in Therapeutic Monoclonal Antibodies., PMID:38986034
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity., PMID:38953380
Affinity-Resolved Size Exclusion Chromatography Coupled to Mass Spectrometry: A Novel Tool to Study the Attribute-and-Function Relationship in Therapeutic Monoclonal Antibodies., PMID:38986034
One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure., PMID:38948809
One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure., PMID:38948809
Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells., PMID:38886892
Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells., PMID:38886892
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:38798522
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:38798522
A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αvβ3 for treating cancer and regulating the tumor microenvironment., PMID:38761419
Druggability properties of a L309K mutation in the antibody CH2 domain., PMID:38742229
Redirect Tropism of Fowl Adenovirus 4 Vector by Modifying Fiber2 with Variable Domain of Heavy-Chain Antibody., PMID:38674401
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting., PMID:38649997
FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder., PMID:38579568
FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder., PMID:38579568
Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC., PMID:38575779
Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC., PMID:38575779
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice., PMID:38490714
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191., PMID:38473239
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191., PMID:38473239
Site-Specific Glycosylation Analysis of Murine and Human Fcγ Receptors Reveals High Heterogeneity at Conserved N-Glycosylation Site., PMID:38363599
Site-Specific Glycosylation Analysis of Murine and Human Fcγ Receptors Reveals High Heterogeneity at Conserved N-Glycosylation Site., PMID:38363599
For research use only. Not for human or drug use.
